Y H Park1, S J Lee1, E Y Cho2, Y La Choi2, J E Lee3, S J Nam3, J-H Yang3, J H Shin4, E Y Ko4, B-K Han4, J S Ahn1, Y-H Im5. 1. Division of Hematology-Oncology, Department of Medicine. 2. Department of Pathology. 3. Department of Surgery. 4. Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 5. Division of Hematology-Oncology, Department of Medicine. Electronic address: imyh00@skku.edu.
Abstract
BACKGROUND: There has been reported that the association between nodal spread and tumor size was disrupted in triple-negative breast cancer (TNBC) and it showed characteristically early relapse. The TNM (tumor-node-metastasis) staging system might not be equally effective as a prognostic indicator for all subtypes. The aim of our study was to evaluate the usefulness of the staging according to subtypes. PATIENTS AND METHODS: We conducted a retrospective analysis of invasive breast cancer patients who received curative surgery at Samsung Medical Center from 2000 to 2004. Relapse-free survivals (RFS) by stage were analyzed. RESULTS: Thousand eight hundred and seventy-nine patients who were available clinicopathologic data were included. These patients were divided into three subtypes: hormone receptor (HR)+, human epidermal growth factor receptor 2+, and triple negative groups. As the stage became more advanced, the slope of each stage of the RFS curves of patients with HR+ and HER2+ steadily increased. In contrast, RFS curves intermingled and showed overlap from stage 1 to 3A in TNBC patients. There was only wide separation of RFS curves between stage 1-3A and 3B-3C in TNBC. CONCLUSIONS: The current TNM staging system might not be enough for encompassing the tumor biology and for predicting outcomes to make therapeutic decisions for all BCs, especially for TNBC patients.
BACKGROUND: There has been reported that the association between nodal spread and tumor size was disrupted in triple-negative breast cancer (TNBC) and it showed characteristically early relapse. The TNM (tumor-node-metastasis) staging system might not be equally effective as a prognostic indicator for all subtypes. The aim of our study was to evaluate the usefulness of the staging according to subtypes. PATIENTS AND METHODS: We conducted a retrospective analysis of invasive breast cancerpatients who received curative surgery at Samsung Medical Center from 2000 to 2004. Relapse-free survivals (RFS) by stage were analyzed. RESULTS: Thousand eight hundred and seventy-nine patients who were available clinicopathologic data were included. These patients were divided into three subtypes: hormone receptor (HR)+, human epidermal growth factor receptor 2+, and triple negative groups. As the stage became more advanced, the slope of each stage of the RFS curves of patients with HR+ and HER2+ steadily increased. In contrast, RFS curves intermingled and showed overlap from stage 1 to 3A in TNBC patients. There was only wide separation of RFS curves between stage 1-3A and 3B-3C in TNBC. CONCLUSIONS: The current TNM staging system might not be enough for encompassing the tumor biology and for predicting outcomes to make therapeutic decisions for all BCs, especially for TNBC patients.
Authors: Mariana Chavez-MacGregor; Elizabeth A Mittendorf; Christina A Clarke; Daphne Y Lichtensztajn; Kelly K Hunt; Sharon H Giordano Journal: Oncologist Date: 2017-06-07
Authors: Min Yi; Elizabeth A Mittendorf; Janice N Cormier; Thomas A Buchholz; Karl Bilimoria; Aysegul A Sahin; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Sheng Luo; Aman U Buzdar; Jaime R Crow; Henry M Kuerer; Kelly K Hunt Journal: J Clin Oncol Date: 2011-11-14 Impact factor: 44.544
Authors: Hyun Ae Jung; Yeon Hee Park; Moonjin Kim; Sungmin Kim; Won Jin Chang; Moon Ki Choi; Jung Yong Hong; Seok Won Kim; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam; Jin Seok Ahn; Young-Hyuck Im Journal: Tumour Biol Date: 2014-10-19
Authors: Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa Journal: Rep Pract Oncol Radiother Date: 2013-09-26